Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21043059 | 0.91 | CHRM1 (0.62) | CHRM1 | |
| SCHEMBL16593254 | 0.89 | CHRM1 (0.80) | CHRM1 | |
| SCHEMBL16593376 | 0.88 | CHRM1 (0.76) | CHRM1 | |
| SCHEMBL16593500 | 0.86 | CHRM1 (0.76) | CHRM1 | |
| SCHEMBL16549772 | 0.86 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL17889156 | 0.86 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL16549787 | 0.86 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL16549771 | 0.86 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL17904755 | 0.85 | CHRM1 (0.98) | CHRM1 | |
| SCHEMBL17903300 | 0.85 | CHRM1 (0.98) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052496-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2018-11-28 | — | — | EP | claimed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | claimed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | claimed |
| EP-3489237-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3489237-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3489237-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489237-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3052496-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-10072005-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-09-11 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-9926312-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-9926312-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| WO-2015049574-A1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-09 | — | — | WO | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072005-B2 | 4-azaindole derivatives | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885 |
| US-20160244445-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885 |
| US-20180208593-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885 |
| US-20150094328-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.